Curetis

Beleggen in aandelen beurs Amsterdam, AEX en AMX index, etc.
Plaats reactie
Hunter
Forum elite
Forum elite
Berichten: 3840
Lid geworden op: 01 Sep 2013 14:05
waarderingen: 898
Contact:

Curetis

Berichtdoor Hunter » 14 Okt 2015 09:23


Biotechbedrijf Curetis naar beurs Amsterdam
Gepubliceerd op 14 okt 2015 om 08:28

HOLZGERLINGEN (AFN) - Het Duitse biotechnologiebedrijf Curetis wil naar de beurs in Amsterdam en Brussel. Dat maakte de onderneming woensdag bekend.

Curetis werkt aan producten waarmee levensbedreigende infectieziekten sneller kunnen worden opgespoord, en waarmee kan worden vastgesteld of sprake is van resistentie tegen antibiotica. Daarmee kunnen artsen snel een goed behandelplan opstellen voor ernstig zieke patiënten.

Volgens Curetis wordt het mogelijk binnen vier tot vijf uur een diagnose te stellen, terwijl daar in ziekenhuizen nu nog dagen tot zelfs weken overheen gaan. Het in 2007 opgerichte bedrijf zegt een goede positie te hebben in de snelgroeiende markt voor diagnostiek.

Financiële details vermeldt Curetis niet. Wel laat het weten dat enkele bestaande aandeelhouders hebben toegezegd bij de beursgang voor circa 15 miljoen euro aan stukken te zullen kopen. De opbrengst wordt onder meer gebruikt voor onderzoek, uitbreiding van de productiecapaciteit en om een Amerikaanse verkooporganisatie op te tuigen.


Hunter
Forum elite
Forum elite
Berichten: 3840
Lid geworden op: 01 Sep 2013 14:05
waarderingen: 898
Contact:

Re: Curetis

Berichtdoor Hunter » 19 Aug 2016 14:28

Biotechnoloog Curetis halveert verlies
Vandaag, 08:32

AMSTERDAM (AFN) - Het Duitse biotechnologiebedrijf Curetis heeft in de eerste helft van dit jaar een nettoverlies van 6,7 miljoen euro geboekt, tegen een min van 12,4 miljoen euro een jaar eerder. Dat meldde het aan de beurs in Amsterdam genoteerde bedrijf vrijdag. Het wegvallen van een grote financieringspost pakte positief uit.

De opbrengsten voor Curetis kwamen uit op 655.000 euro, tegen 742.000 euro een jaar eerder. Het bedrijf verwacht dat de inkomsten voorlopig nog sterk zullen fluctueren van kwartaal tot kwartaal omdat de verkopen aan distributiepartners oneven zijn verdeeld over het jaar. De uitgaven bedroegen 7,5 miljoen euro, van 6,4 miljoen euro vorig jaar. Dat had te maken met hogere kosten voor onderzoek en ontwikkeling en gestegen distributiekosten.

Het bedrijf maakt bloedtestsystemen (Unyvero) waarmee levensbedreigende infectieziekten sneller kunnen worden opgespoord, en waarmee kan worden vastgesteld of sprake is van resistentie tegen antibiotica. Daarmee kunnen artsen snel een goed behandelplan opstellen voor ernstig zieke patiënten.

Curetis had eind juni een kaspositie van 39,7 miljoen, tegen 46,2 miljoen euro aan het einde van 2015. De zogenoemde cashburn was in de eerste helft van het jaar 6,4 miljoen euro. Curetis voorziet een kaspositie van 31 miljoen tot 32 miljoen euro aan het einde van dit jaar.

Hunter
Forum elite
Forum elite
Berichten: 3840
Lid geworden op: 01 Sep 2013 14:05
waarderingen: 898
Contact:

Re: Curetis

Berichtdoor Hunter » 06 Sep 2016 09:19


Curetis lanceert upgrade bloedtestsysteem
Gepubliceerd op 6 sep 2016 om 08:55

AMSTERDAM (AFN) - Het Duitse biotechnologiebedrijf Curetis staat voor de lancering van een volgende generatie bloedtestsystemen (Unyvero) waarmee levensbedreigende infectieziekten sneller kunnen worden opgespoord. De lancering volgt op een positieve beoordeling van het apparaatje.

De Unyvero ITI wordt verkrijgbaar met een uitgebreid paneel en een verbeterde gevoeligheid. Het apparaat komt in het lopende kwartaal op de Europese markt.
De Unyvero ITI is ontworpen voor de diagnose van vele soorten ernstige infecties. Het apparaat kan 102 diagnostische doelen stellen, waaronder de 85 meest klinisch relevante pathogene micro-organismen. De eerste generatie apparaten had een bereik van 80 diagnostische doelen.

bertje
Forum elite
Forum elite
Berichten: 4341
Lid geworden op: 30 Jul 2012 14:53
waarderingen: 981
Contact:

Re: Curetis

Berichtdoor bertje » 08 Sep 2016 09:59

niet slecht bezig:

Curetis Acquires Patents and Rights to Genetic Antibiotic
Resistance and Susceptibility (GEAR) Database and Know-How
from Siemens
- Agreement gives Curetis worldwide rights to database and IP based on Next Generation
Sequencing
- GEAR significantly enhances Curetis’ leading position in the area of genetic
antimicrobial resistance biomarker testing
Amsterdam, the Netherlands, and Holzgerlingen, Germany, September 7, 2016 -- Curetis
N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of next-level
molecular diagnostic solutions, today announced the signing of an asset acquisition agreement
with the Siemens Technology Accelerator GmbH (STA). Under the terms of the agreement,
Curetis has acquired sole commercial rights from STA to the GEAR GEnetic Antibiotic
Resistance and Susceptibility platform and database with all its content, numerous GEAR-related
patents and patent applications, as well as all corresponding know-how. The deal gives Curetis
sole worldwide product development and commercial rights, including the right to sublicense in
the fields of human and animal diagnostics as well as food safety testing. Furthermore, Curetis has
secured the sole rights to leverage the GEAR assets in collaboration with pharmaceutical
companies for the development of novel antimicrobial drugs for human and animal health.
As consideration for these assets, STA will receive an undisclosed upfront payment from Curetis.
Furthermore, Curetis will make undisclosed milestone payments for products including GEAR
biomarkers upon first CE IVD marking and first FDA approval (or similar regulatory clearance),
respectively. Also, there will be royalty payments to STA in industry-typical percentage ranges on
future products based on use of the GEAR platform or GEAR biomarkers. Further financial
details were not disclosed.
The state-of-the-art GEAR bioinformatics platform and database was developed and compiled in
collaboration with two academic partners: The Institute of Clinical Molecular Biology (IKMB) at
Kiel University that carried out the next generation sequencing (NGS) of bacterial isolates and the
Clinical Bioinformatics Group of Saarland University headed by Prof. Dr. Andreas Keller that
developed the bioinformatics platform and performed the computational analysis of 30 Terabyte
of data underlying the GEAR database. GEAR allows users to assemble and annotate bacterial
genomes from NGS raw data, identify genetic variations in those genomes and correlate those
with the response of the respective bacterial strain to antibiotics. Currently, the GEAR database
contains the entire DNA sequences as well as sensitivity data for 21 antibiotics of more than
11,000 bacterial strains isolated from patient samples across the world over the last three decades.
It will allow Curetis to rapidly identify potential novel biomarkers, biomarker combinations, and
algorithms predicting antibiotic resistance, as well as potential novel targets for antimicrobial
drugs.
The acquisition of the GEAR database and patent estate adds significantly to the leadership
position that Curetis has established in the area of genetic antimicrobial resistance biomarker
testing with its Unyvero Application Cartridges. Curetis will further expand and mine the GEAR
database in collaboration with leading academic institutions as well as pharmaceutical and
diagnostics companies and leverage those into commercial products on its Unyvero Molecular
Diagnostics platform and beyond.
“We are thrilled to have won in the competitive bidding process for this unique and exciting
asset,” said Dr. Achim Plum, Chief Commercial Officer of Curetis. “With this platform, we are
planning to build a network of strong and collaborative relationships with academics, clinicians
and companies in the fields of diagnostics and pharmaceuticals alike. We will develop this
repository into a valuable resource of antibiotic resistance biomarkers available to the global
research community, while leveraging the proprietary nature of GEAR into our own Unyvero
products and platform in the future.”
Oliver Schacht, CEO of Curetis, added, “Since our IPO, we have diligently executed on our
commercial and product development plans. At the same time, we have kept our eyes open for
strategic opportunities such as the GEAR acquisition. GEAR allows us to significantly expand the
scale and scope of the Unyvero platform and complement it with NGS-based knowledge. GEAR
will become an engine for even more comprehensive and differentiated content of antibiotic
resistance biomarkers in our Unyvero products and allow us to stay on top of the development of
cutting-edge molecular diagnostic products for critical hospital infections.”
Prof. Keller, one of the initiators of the project, highlighted the broad and unique character of
GEAR: “The more than 11,000 whole bacterial genomes collected over three decades and across
many countries in combination with culture-based phenotypic resistance profiles against 21 drugs
enabled us to investigate multivariate genetic resistance mechanisms in a very comprehensive
manner”. Prof. Keller also underlined that Curetis is a perfect partner for commercialization of
tests for antibiotic resistance derived from GEAR: “We are convinced of the success of genetic
antibiotic resistance tests and committed to support Curetis in their endeavor to improve care for
patients suffering from bacterial infections”
About the GEAR Database and Assets:
The GEAR database includes genomic data of mostly Gram negative bacteria causing pneumonia,
bloodstream infections, urinary tract infections, and gastric and wound infections. Samples were
carefully selected across multiple geographies (USA, EU, Asia) and have been collected over
three decades to reflect resistance development and variability over time. Sample collection was
done at over 200 sites on 5 continents, with over 150 US institutes contributing. In addition to
many of the most troublesome Gram negative bacteria, GEAR also includes S. aureus,
demonstrating feasibility also for Gram positive bacteria.
Sample collection was designed to achieve significant statistical power with over 10,000 Gram
negative bacterial strains and ca. 1,000 S. aureus (both MSSA and MRSA) strains tested. Overall,
21 antibiotic drugs in 182 different concentrations with all modes of action for resistance were
tested for. Most commonly used drugs have been chosen by the former Siemens Microbiology
Department. Antibiotic susceptibility testing (AST) reference methods as per CLSI (Clinical and
Laboratory Standards Institute) guidelines were used and results interpreted according to
EUCAST (European Committee on Antimicrobial Susceptibility Testing) guidelines. Seven out of
nine combinations of bacteria and antibiotics identified as being of international concern by the
WHO were analyzed in detail. Individual patent filings have been made for each bacteria for all
antibiotics as well as certain method and process patents.
Next generation sequencing (NGS) was performed at one of the leading German Sequencing
Centers (IKMB Institute of Clinical Molecular Biology in Kiel) on HiSeq 2000 and HiSeq 2500
Sequencers with over 300 Mio bases sequenced per sample. Taken together, 4 billion reads with
0.4 trillion bases were sequenced. Advanced bioinformatics approaches developed by the group of
Prof. Dr. Andreas Keller, Chair for Clinical Bioinformatics, Saarland University, were employed
to combine NGS results with AST data to identify potential novel and proprietary antibiotic
resistance biomarkers and biomarker combinations.
GEAR enables a wide range of valuable clinical applications such as better genetic resistance
testing for specific drug classes, broader syndromic resistance biomarker panels, and, in the
future, potentially fully genetic antibiograms. It therefore can provide unique content for high-,
medium-, and low-plexed MDx platforms.

bertje
Forum elite
Forum elite
Berichten: 4341
Lid geworden op: 30 Jul 2012 14:53
waarderingen: 981
Contact:

Re: Curetis

Berichtdoor bertje » 08 Sep 2016 10:53

Curetis voert vandaag de ranglijst in Brussel aan. Het biotechbedrijf verwierf de rechten op een databank met informatie om de oplopende resistentie tegen antibiotica aan te pakken. Curetis betaalt daarvoor een niet nader bepaalde som aan de Siemens Technology Accelerator en mijlpaalbetalingen als er ook middelen uitkomen en omzet wordt geboekt. De databank omvat gegevens en stalen van 30 jaar onderzoek over bacteriële genomen, hun DNA-variaties en hoe ze reageren op antibiotica.

Degroof Petercam herhaalt naar aanleiding van het nieuws het koopadvies en koersdoel van 10 euro voor Curetis.

bertje
Forum elite
Forum elite
Berichten: 4341
Lid geworden op: 30 Jul 2012 14:53
waarderingen: 981
Contact:

Re: Curetis

Berichtdoor bertje » 08 Sep 2016 12:03

De weerstand neemt af, boven de 7 vandaag zou geen verrassing zijn.
6,74 412 1
6,75 1.000 1
6,821 80 1
6,986 350 1
6,987 10 1
7 1.383 3
7,1 482 1
7,17 1.000 1
7,35 5 1
7,45 2.100 2

Hunter
Forum elite
Forum elite
Berichten: 3840
Lid geworden op: 01 Sep 2013 14:05
waarderingen: 898
Contact:

Re: Curetis

Berichtdoor Hunter » 05 Jan 2017 09:45

Curetis vraagt toestemming gebruik Unyvero in Amerika
Donderdag 5 januari 2017 08:50

Unyvero levert snellere resultaten dan traditionele methode. (ABM FN-Dow Jones) Curetis heeft bij de Amerikaanse medische toezichthouder FDA toestemming gevraagd voor het gebruik van zijn Unyvero diagnostische platform en de bijbehorende module voor de diagnose van infecties van de lagere luchtwegen. Dit maakte het biotechbedrijf donderdag voorbeurs bekend.

De aanvraag is gebaseerd op de resultaten van een klinisch onderzoek, dat aantoonde dat het Unyvero-platform in ongeveer vijf uur resultaten geeft, terwijl de traditionele kweek-methode drie tot vier dagen in beslag neemt.
Op een rood Damrak sloot het aandeel Curetis woensdag 0,9 procent op 6,56 euro.

bertje
Forum elite
Forum elite
Berichten: 4341
Lid geworden op: 30 Jul 2012 14:53
waarderingen: 981
Contact:

Re: Curetis

Berichtdoor bertje » 10 Apr 2017 13:17

Curetis to Present Data from Unyvero LRT U.S. FDA Clinical Trial at ASM Microbe
- U.S. data set complemented by recent clinical study data from European hospital
Amsterdam, the Netherlands, and Holzgerlingen, Germany, April 10, 2017 -- Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that significant clinical data updates on its Unyvero System and P55 / LRT cartridge for the diagnosis of pneumonia and lower respiratory tract infections will be presented at ASM Microbe 2017, being held June 1-5 in New Orleans, LA.
Detailed data from Curetis’ U.S. FDA clinical study of the Unyvero System and the LRT cartridge for the diagnosis of lower respiratory tract infections will be presented by Dr Matthew Sims, Director, Infectious Diseases Research at Beaumont Research Institute and one of the U.S. FDA study’s principal investigators. Dr Sims will present the study during an oral presentation titled Multicenter Evaluation of the Curetis Lower Respiratory Tract Infection Cartridge on the Unyvero-Platform in session 481, “Pneumonia: Novel Epidemiology, Novel Approaches” (June 5, 2017, 12:15-12:30 PM, Room 208).
In addition, Dr Sims will present clinical data from the portion of the study conducted at Beaumont Hospital, Royal Oak, MI. His presentation Potential Impact of Rapid Diagnostics in Management of Suspected Pneumonia, will be given in the session “Antimicrobial and Diagnostic Stewardship” (June 2, 2017, 12:45-2:45 PM, Exhibit Hall D, Exhibit and Poster Hall).
The U.S. data on the P55/LRT cartridge are complemented by recent findings of researchers at the Institute of Medical Microbiology, University Hospital Essen (Essen, Germany), who published data concluding that the "Unyvero Application is a useful diagnostic tool for the early and rapid detection of pathogens in respiratory specimens”. They reported a significantly higher detection rate when using Unyvero as compared to culture methods and a considerably reduced time-to-result, from a median of 48h to a median of 7.5 hours. The team has tested the Unyvero P55 pneumonia application cartridge in daily clinical routine with 439 respiratory specimens of 342 patients. Results from the European Study were presented during this year’s 5th Joint Conference of the DGHM & VAAM / VAAM Annual Meeting 2017 and published in Schmidt D et al., Early and Rapid Detection of Respiratory Pathogens: A Commercial Multiplex PCR Assay in Comparison with Culture. Biospektrum Abstractbook Microbiology and Infection 2017, Heidelberg 2017, p. 131 – DOI: 10.1007/s12268-017-0772-x).
“We are excited that new clinical data on our Unyvero P55 / LRT cartridges, which are in line with our findings from various CE performance evaluation studies, have been published in this peer-reviewed format,” said Johannes Bacher, COO of Curetis. “They demonstrate the performance of Unyvero in terms of sensitivity and specificity, and also confirm the substantial advantage in terms of time-to-results. Moreover, we are proud that the data from our U.S. FDA trial were selected for an oral presentation at the upcoming ASM Microbe meeting.
He added that new studies are upcoming in the U.S. and the EU to further investigate clinical benefit and impact of the Unyvero P55/LRT cartridge.
###
About Curetis
Founded in 2007, Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis enable rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with other techniques.
To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and Euronext Brussels and private equity funds of over EUR 63.5 million. Furthermore, Curetis has entered into a debt financing facility with EIB for up to EUR 25 million. The company is based in Holzgerlingen near Stuttgart, Germany. Curetis collaborates with Heraeus Medical, pharmaceutical companies, and has entered into several international distribution agreements covering many countries across Europe, the Middle East and Asia.
In 2017, Curetis established Ares Genetics GmbH, a wholly-owned subsidiary of Curetis GmbH in Vienna, Austria. Ares Genetics is dedicated to maximize the R&D and related scientific and business opportunities of the GEAR assets acquired in 2016 for the entire Curetis Group.
For further information, please visit http://www.curetis.com.

Hunter
Forum elite
Forum elite
Berichten: 3840
Lid geworden op: 01 Sep 2013 14:05
waarderingen: 898
Contact:

Re: Curetis

Berichtdoor Hunter » 12 Apr 2017 08:05

Curetis stelt medisch adviseur aan
Gepubliceerd op 12 apr 2017 om 07:41

AMSTERDAM (AFN) - Curetis heeft de Amerikaanse hoogleraar Melissa Miller aangesteld als medisch adviseur van het biotechnologiebedrijf. Dat bleek woensdag. Ze neemt zitting in de zogenoemde Medical Advisory Board van de onderneming, die een notering heeft op de beurs in Amsterdam.

Het bedrijf nomineert verder Nils Clausnitzer als lid van de raad van commissarissen. Zijn verkiezing staat op de agenda van de aandeelhoudersvergadering in juni.

bertje
Forum elite
Forum elite
Berichten: 4341
Lid geworden op: 30 Jul 2012 14:53
waarderingen: 981
Contact:

Re: Curetis

Berichtdoor bertje » 19 Apr 2017 11:48

De verkopers druipen terug af, kan hier plots snel gaan.
5,626 32 1
5,627 384 1
5,64 117 1
5,65 300 1
5,695 200 1
5,729 261 1
5,75 1.000 1
5,8 200 1
6,15 1.055
2 6,17 850 2

Vorige week dinsdag stonden we ook nog 6.25.